INTRODUCTION
Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, affects approximately eight million individuals in Latin America. 1 CD is characterized by a short acute phase defined by patent parasitemia and a long and progressive chronic phase. Up to 40%-50% of chronically infected patients develop progressive cardiomyopathy and/or motility disturbances of the esophagus and colon. The available chemotherapy for CD is not satisfactory depending on two heterocyclic agents, nifurtimox and benznidazole. 2 Naphthoquinones are considered privileged structures in medicinal chemistry due to their structural properties and biological activities. Recently, we have described the synthesis, trypanocidal and leishmanicidal activity of lapachone-based 1,2,3-triazoles. 3 In this context, herein we describe the synthesis and evaluation against T. cruzi of 1,2,3-triazole substituted paraand ortho-naphthoquinones.
RESULTS AND DISCUSSION
Compounds 1-10, N-phthalimidoalkyl-azides, and 11-12 were initially synthesized and used in a click chemistry reaction with substituted 2-(prop-2-yn-1-ylamine)-naphthoquinone to obtain the respective triazole compounds in high yields (Scheme 1).
Scheme 1. Obtention of para-quinones 1-12.
Ortho-quinones were synthesized from the intermediate azide 13 previously described. 3 To prepare the novel derivatives 14-16, naphthoquinones substituted by a terminal alkyne were obtained and used in the click chemistry reaction (Scheme 2). Nor-β-lapachone derivatives 14-16 were isolated in moderate yields.
Scheme 2. Obtention of ortho-quinones 14-15.
The substances 1-12 were not active against T. cruzi with IC 50 /24h > 4000 µM. Compounds 14-15 was planned in order to obtain ortho-quinonecoupled to para-quinoidal structure (Scheme 2). Our strategy was effective and the substances 14-16 presented IC 50 /24 h values = 80.8, 6.8 and 8.2 µM, respectively. When compared with benznidazole, the standard drug used against T. cruzi, compounds 15 and 16 were fifteen and twelve times more active than anti-T. cruzi drug benznidazole.
CONCLUSION
We synthesized and evaluated fifteen substances and three potent trypanocidal compounds were identified, more active than the anti-T. cruzi drug benznidazole, the standard anti-T. cruzi drug. Compound 15 was fifteen times more active than benznidazole and this substance is a promising candidate for further investigations.
